Genomics and Interventional Oncology in Metastatic Liver Cancer

Abstract

This review aims to investigate the current literature on genetic and genomic biomarkers of locoregional interventions on metastatic liver metastases. A brief overview on the most common cancers that metastasize to the liver and the role locoregional therapies, such as ablation, chemoembolization, and radioembolization, play in their treatment will be presented. Review of the literature on the genetic, metabolic, and other molecular biomarkers and how they relate to posttreatment survival and outcomes will be discussed. Evaluation of how the existing data can better inform decisions regarding locoregional treatments in those patients with metastatic lesions of the liver will be completed. Personalized treatment paradigms in different types of metastatic cancer present significant opportunities for improved overall clinical outcomes. Optimizing patient selection for localized treatments is vital to improving outcomes and determining which biomarkers correlate with improved efficacy presents many avenues for future research.

Keywords

genetics - genomics - biomarkers - liver metastases - locoregional therapy - interventional oncology

• References

• 1 Ayoub JP, Hess KR, Abbruzzese MC, Lenzi R, Raber MN, Abbruzzese JL. Unknown primary tumors metastatic to liver. J Clin Oncol 1998; 16 (06) 2105-2112
• 2 Hoe AL, Royle GT, Taylor I. Breast liver metastases--incidence, diagnosis and outcome. J R Soc Med 1991; 84 (12) 714-716
• 3 Görög D, Tóth A, Weltner J. Prognosis of untreated liver metastasis from rectal cancer. Acta Chir Hung 1997; 36 (1-4): 106-107
• 4 Ferlito A, Shaha AR, Silver CE, Rinaldo A, Mondin V. Incidence and sites of distant metastases from head and neck cancer. ORL J Otorhinolaryngol Relat Spec 2001; 63 (04) 202-207
• 5 Devita VT, Hellman S, Rosenberg SA. , eds. Cancer: Principles and Practice of Oncology. 6th ed. Philadelphia: Lippincott Williams and Wilkins; 2001
• 6 Geoghegan JG, Scheele J. Treatment of colorectal liver metastases. Br J Surg 1999; 86 (02) 158-169
• 7 Wei AC, Greig PD, Grant D, Taylor B, Langer B, Gallinger S. Survival after hepatic resection for colorectal metastases: a 10-year experience. Ann Surg Oncol 2006; 13 (05) 668-676
• 8 Gallagher DJ, Kemeny N. Metastatic colorectal cancer: from improved survival to potential cure. Oncology 2010; 78 (3-4): 237-248
• 9 Mahnken AH, Pereira PL, de Baère T. Interventional oncologic approaches to liver metastases. Radiology 2013; 266 (02) 407-430
• 10 Rous P, Larimore LD. Relation of the portal blood to liver maintenance: a demonstration of liver atrophy conditional on compensation. J Exp Med 1920; 31 (05) 609-632
• 11 Madoff DC, Abdalla EK, Vauthey JN. Portal vein embolization in preparation for major hepatic resection: evolution of a new standard of care. J Vasc Interv Radiol 2005; 16 (06) 779-790
• 12 van Riel JM, van Groeningen CJ, Kedde MA. , et al. Continuous administration of irinotecan by hepatic arterial infusion: a phase I and pharmacokinetic study. Clin Cancer Res 2002; 8 (02) 405-412
• 13 Allen-Mersh TG, Earlam S, Fordy C, Abrams K, Houghton J. Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet 1994; 344 (8932): 1255-1260
• 14 Rougier P, Laplanche A, Huguier M. , et al. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J Clin Oncol 1992; 10 (07) 1112-1118
• 15 Kemeny NE, Niedzwiecki D, Hollis DR. , et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol 2006; 24 (09) 1395-1403
• 16 Elias D, Goere D, Boige V. , et al. Outcome of posthepatectomy-missing colorectal liver metastases after complete response to chemotherapy: impact of adjuvant intra-arterial hepatic oxaliplatin. Ann Surg Oncol 2007; 14 (11) 3188-3194
• 17 Kemeny NE, Melendez FD, Capanu M. , et al. Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol 2009; 27 (21) 3465-3471
• 18 Vogl TJ, Mack MG, Balzer JO. , et al. Liver metastases: neoadjuvant downsizing with transarterial chemoembolization before laser-induced thermotherapy. Radiology 2003; 229 (02) 457-464
• 19 Aliberti C, Fiorentini G, Muzzio PC. , et al. Trans-arterial chemoembolization of metastatic colorectal carcinoma to the liver adopting DC Bead®, drug-eluting bead loaded with irinotecan: results of a phase II clinical study. Anticancer Res 2011; 31 (12) 4581-4587
• 20 Vogl TJ, Gruber T, Balzer JO, Eichler K, Hammerstingl R, Zangos S. Repeated transarterial chemoembolization in the treatment of liver metastases of colorectal cancer: prospective study. Radiology 2009; 250 (01) 281-289
• 21 Lewandowski RJ, Geschwind JF, Liapi E, Salem R. Transcatheter intraarterial therapies: rationale and overview. Radiology 2011; 259 (03) 641-657
• 22 Gupta S, Johnson MM, Murthy R. , et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 2005; 104 (08) 1590-1602
• 23 Vogl T, Eichler K, Zangos S. , et al. Preliminary experience with transarterial chemoembolization (TACE) in liver metastases of uveal malignant melanoma: local tumor control and survival. J Cancer Res Clin Oncol 2007; 133 (03) 177-184
• 24 Christante D, Pommier S, Givi B, Pommier R. Hepatic artery chemoinfusion with chemoembolization for neuroendocrine cancer with progressive hepatic metastases despite octreotide therapy. Surgery 2008; 144 (06) 885-893 , discussion 893–894
• 25 Martin RC, Joshi J, Robbins K. , et al. Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study. Ann Surg Oncol 2011; 18 (01) 192-198
• 26 Albert M, Kiefer MV, Sun W. , et al. Chemoembolization of colorectal liver metastases with cisplatin, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol. Cancer 2011; 117 (02) 343-352
• 27 Ariel IM, Padula G. Treatment of symptomatic metastatic cancer to the liver from primary colon and rectal cancer by the intraarterial administration of chemotherapy and radioactive isotopes. J Surg Oncol 1978; 10 (04) 327-336
• 28 Dawson LA, McGinn CJ, Normolle D. , et al. Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J Clin Oncol 2000; 18 (11) 2210-2218
• 29 Van den Eynde M, Flamen P, El Nakadi I. , et al. Inducing resectability of chemotherapy refractory colorectal liver metastasis by radioembolization with yttrium-90 microspheres. Clin Nucl Med 2008; 33 (10) 697-699
• 30 Hendlisz A, Van den Eynde M, Peeters M. , et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol 2010; 28 (23) 3687-3694
• 31 Chua TC, Bester L, Saxena A, Morris DL. Radioembolization and systemic chemotherapy improves response and survival for unresectable colorectal liver metastases. J Cancer Res Clin Oncol 2011; 137 (05) 865-873
• 32 Kennedy AS, Nutting C, Jakobs T. , et al. A first report of radioembolization for hepatic metastases from ocular melanoma. Cancer Invest 2009; 27 (06) 682-690
• 33 Jakobs TF, Hoffmann RT, Fischer T. , et al. Radioembolization in patients with hepatic metastases from breast cancer. J Vasc Interv Radiol 2008; 19 (05) 683-690
• 34 Gonsalves CF, Eschelman DJ, Sullivan KL, Anne PR, Doyle L, Sato T. Radioembolization as salvage therapy for hepatic metastasis of uveal melanoma: a single-institution experience. AJR Am J Roentgenol 2011; 196 (02) 468-473
• 35 Cao CQ, Yan TD, Bester L, Liauw W, Morris DL. Radioembolization with yttrium microspheres for neuroendocrine tumour liver metastases. Br J Surg 2010; 97 (04) 537-543
• 36 Ahmed M, Brace CL, Lee Jr FT, Goldberg SN. Principles of and advances in percutaneous ablation. Radiology 2011; 258 (02) 351-369
• 37 Thomson KR, Cheung W, Ellis SJ. , et al. Investigation of the safety of irreversible electroporation in humans. J Vasc Interv Radiol 2011; 22 (05) 611-621
• 38 Abitabile P, Hartl U, Lange J, Maurer CA. Radiofrequency ablation permits an effective treatment for colorectal liver metastasis. Eur J Surg Oncol 2007; 33 (01) 67-71
• 39 Sgouros J, Cast J, Garadi KK. , et al. Chemotherapy plus percutaneous radiofrequency ablation in patients with inoperable colorectal liver metastases. World J Gastrointest Oncol 2011; 3 (04) 60-66
• 40 Ruers T, Van Coevorden F, Punt CJ. , et al; European Organisation for Research and Treatment of Cancer (EORTC); Gastro-Intestinal Tract Cancer Group; Arbeitsgruppe Lebermetastasen und tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO); National Cancer Research Institute Colorectal Clinical Study Group (NCRI CCSG). Local treatment of unresectable colorectal liver metastases: results of a randomized phase II trial. J Natl Cancer Inst 2017 109(09):
• 41 Akyildiz HY, Mitchell J, Milas M, Siperstein A, Berber E. Laparoscopic radiofrequency thermal ablation of neuroendocrine hepatic metastases: long-term follow-up. Surgery 2010; 148 (06) 1288-1293 , discussion 1293
• 42 Mazzaglia PJ, Berber E, Milas M, Siperstein AE. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival. Surgery 2007; 142 (01) 10-19
• 43 Shady W, Petre EN, Vakiani E. , et al. Kras mutation is a marker of worse oncologic outcomes after percutaneous radiofrequency ablation of colorectal liver metastases. Oncotarget 2017; 8 (39) 66117-66127
• 44 Jiang BB, Yan K, Zhang ZY. , et al. The value of KRAS gene status in predicting local tumor progression of colorectal liver metastases following radiofrequency ablation. Intl J Hyperthermia. 2019; 36 (01) 211-219
• 45 Odisio BC, Yamashita S, Huang SY. , et al. Local tumour progression after percutaneous ablation of colorectal liver metastases according to RAS mutation status. Br J Surg 2017; 104 (06) 760-768
• 46 Calandri M, Odisio BC. Tailoring ablation strategies for colorectal liver metastases based upon rat sarcoma viral oncogene mutation status. Linchuang Zhongliuxue Zazhi 2019; 8 (05) 51
• 47 Lahti SJ, Xing M, Zhang D, Lee JJ, Magnetta MJ, Kim HS. KRAS status as an independent prognostic factor for survival after yttrium-90 radioembolization therapy for unresectable colorectal cancer liver metastases. J Vasc Interv Radiol 2015; 26 (08) 1102-1111
• 48 Magnetta MJ, Ghodadra A, Lahti SJ, Xing M, Zhang D, Kim HS. Connecting cancer biology and clinical outcomes to imaging in KRAS mutant and wild-type colorectal cancer liver tumors following selective internal radiation therapy with yttrium-90. Abdom Radiol (NY) 2017; 42 (02) 451-459
• 49 Dendy MS, Ludwig JM, Kokabi N. , et al. Genomic mutations and histopathologic biomarkers in Y⁹⁰ radioembolization for chemorefractory colorectal liver metastases. Oncotarget 2018; 9 (65) 32523-32533
• 50 Ziv E, Bergen M, Yarmohammadi H. , et al. PI3K pathway mutations are associated with longer time to local progression after radioembolization of colorectal liver metastases. Oncotarget 2017; 8 (14) 23529-23538
• 51 Melucci E, Cosimelli M, Carpanese L. , et al; Italian Society of Locoregional Therapies in Oncology (S.I.T.I.L.O.). Decrease of survivin, p53 and Bcl-2 expression in chemorefractory colorectal liver metastases may be predictive of radiosensivity after radioembolization with yttrium-90 resin microspheres. J Exp Clin Cancer Res 2013; 32: 13
• 52 Fahmueller YN, Nagel D, Hoffmann RT. , et al. Immunogenic cell death biomarkers HMGB1, RAGE, and DNAse indicate response to radioembolization therapy and prognosis in colorectal cancer patients. Int J Cancer 2013; 132 (10) 2349-2358
• 53 Carpizo DR, Gensure RH, Yu X. , et al. Pilot study of angiogenic response to yttrium-90 radioembolization with resin microspheres. J Vasc Interv Radiol 2014; 25 (02) 297-306.e1
• 54 Simoneau E, Chicoine J, Negi S. , et al. Next generation sequencing of progressive colorectal liver metastases after portal vein embolization. Clin Exp Metastasis 2017; 34 (05) 351-361
• 55 Ziv E, Rice SL, Filtes J. , et al. DAXX mutation status of embolization-treated neuroendocrine tumors predicts shorter time to hepatic progression. J Vasc Interv Radiol 2018; 29 (11) 1519-1526
• 56 Vandamme T, Beyens M, Boons G. , et al. Hotspot DAXX, PTCH2 and CYFIP2 mutations in pancreatic neuroendocrine neoplasms. Endocr Relat Cancer 2019; 26 (01) 1-12
• 57 Jiao Y, Shi C, Edil BH. , et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 2011; 331 (6021): 1199-1203
• 58 Deipolyi AR, Riedl CC, Bromberg J. , et al. Association of PI3K pathway mutations with early positron-emission tomography/CT imaging response after radioembolization for breast cancer liver metastases: results of a single-center retrospective pilot study. J Vasc Interv Radiol 2018; 29 (09) 1226-1235
• 59 Yang J, Wu NN, Huang DJ. , et al. PPFIA1 is upregulated in liver metastasis of breast cancer and is a potential poor prognostic indicator of metastatic relapse. Tumour Biol 2017; 39 (07) 1010428317713492
• 60 Evans DG, Shenton A, Woodward E, Lalloo F, Howell A, Maher ER. Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting: risks of breast/ovarian cancer quoted should reflect the cancer burden in the family. BMC Cancer 2008; 8: 155
• 61 Iborra S, Stickeler E. HER2-orientated therapy in early and metastatic breast cancer. Breast Care (Basel) 2016; 11 (06) 392-397
• 62 Haffty BG, Yang Q, Reiss M. , et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 2006; 24 (36) 5652-5657
• 63 Pinker K, Chin J, Melsaether AN, Morris EA, Moy L. Precision medicine and radiogenomics in breast cancer: new approaches toward diagnosis and treatment. Radiology 2018; 287 (03) 732-747
• 64 Yamamoto S, Han W, Kim Y. , et al. Breast cancer: radiogenomic biomarker reveals associations among dynamic contrast-enhanced MR imaging, long noncoding RNA, and metastasis. Radiology 2015; 275 (02) 384-392
• 65 Abdel Karim N, Eldessouki I, Taftaf A. , et al. GNQ-209P mutation in metastatic uveal melanoma and treatment outcome. Case Rep Oncol Med 2018; 2018: 4256365
• 66 Zaretsky JM, Garcia-Diaz A, Shin DS. , et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med 2016; 375 (09) 819-829
• 67 Rozeman EA, Dekker TJA, Haanen JBAG, Blank CU. Advanced melanoma: current treatment options, biomarkers, and future perspectives. Am J Clin Dermatol 2018; 19 (03) 303-317
• 68 Ni Y, Bi J, Ye X. , et al. Local microwave ablation with continued EGFR tyrosine kinase inhibitor as a treatment strategy in advanced non-small cell lung cancers that developed extra-central nervous system oligoprogressive disease during EGFR tyrosine kinase inhibitor treatment: a pilot study. Medicine (Baltimore) 2016; 95 (25) e3998
• 69 Yu HA, Sima CS, Huang J. , et al. Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors. J Thorac Oncol 2013; 8 (03) 346-351
• 70 Ziv E, Yarmohammadi H, Boas FE. , et al. Gene signature associated with upregulation of the Wnt/β-catenin signaling pathway predicts tumor response to transarterial embolization. J Vasc Interv Radiol 2017; 28 (03) 349-355.e1
• 71 Calandri M, Yamashita S, Gazzera C. , et al. Ablation of colorectal liver metastasis: Interaction of ablation margins and RAS mutation profiling on local tumour progression-free survival. Eur Radiol 2018; 28 (07) 2727-2734